Skip to main content
Premium Trial:

Request an Annual Quote

Agouron Will Establish Division for Oncology

Premium

LA JOLLA, Calif.--Agouron Pharmaceuticals announced its intention to create a separate operating division in which the company's research and development of products for oncology and related fields will be conducted. Under the proposed plan, yet to be approved by shareholders, financial performance of the oncology R&D division would be tracked as separate equity.

Agouron also announced fiscal 1998 net income of $13,154,000, or 40 cents per share, on total revenues of $466,505,000.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.